Etid klinik pou Atak kè nan Tennessee
5 etid pou Atak kè ap chèche patisipan nan sit nan Tennessee.
Vil nan Tennessee
Tèks ofisyèl etid la (Anglè)
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Southeast Renal Research Institute, Chattanooga
- Dialysis Clinic Inc - University Nephology, Knoxville
- Knoxville Kidney Center PLLC, Knoxville
- ak 2 plis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05485961An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
- The Stern Cardiovascular Foundation, Germantown
- Apex Cardiology Research Associates of Jackson, Jackson
- Vanderbilt Univ Medi Cen, Nashville
- ak 1 plis
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Sep 4, 2026 · NCT07517263OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- Erlanger Health, Inc., Chattanooga
- Ascension Saint Thomas, Nashville
- Parkway Cardiology Associates, Oak Ridge
- ak 1 plis
Ap rekriteFaz 3
Laj 50 a 105 · Tout sèks · Mizajou Aug 21, 2026 · NCT07136012Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
- Vanderbilt University Medical Center, Nashville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Mar 24, 2026 · NCT04774159Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence
- University of Tennessee Medical Center, Knoxville
- University of Tennessee Health Science Center/Regional One Health, Memphis
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jan 29, 2026 · NCT06374277Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.